Purpose: We applied a novel combined connectivity mapping and pharmacoepidemiological approach to identify medications that alter breast cancer risk.
reports of higher breast cancer risk among hormone replacement therapy users have led to a sharp decline in its use. 11, 12 Despite the clear benefits of identifying existing medications that alter breast cancer risk, the large number of potential candidates for evaluation makes prioritizing investigations difficult.
Connectivity mapping is an advanced bioinformatics technique
that can be used to identify medications that mimic or reverse the gene-expression profiles induced by a disease. 13, 14 It has previously been used to identify medications with anticancer properties. For instance, cimetidine has been discovered as a potential treatment for lung cancer, 15 and rapamycin has been shown to overcome dexamethasone resistance in acute lymphoblastic leukemia. 14 Pharmacoepidemiology allows the study of the association between medication use and outcomes in humans, quickly and at modest cost. 16 Therefore, a combination of connectivity mapping and pharmacoepidemiology could be used to rapidly identify medications that alter breast cancer risk. This paper aims to apply this approach using population-based data from the UK.
2 | METHODS
| Initial connectivity mapping screening and results
Our application of the connectivity mapping is described briefly in Appendix 1, and more fully elsewhere. 17 Further details of this process are available upon request. The primary outcome of this was the "connectivity score", 14 which is similar to a z-score from a standard normal distribution, and can be interpreted as the strength of agreement between the gene signature of the disease and medication. In this instance, a positive connectivity score indicates a medication with potential cancer-causing properties, while a negative score signifies a medication with potential cancer-preventing properties.
We initially identified 67 medications for inclusion in the analysis 17 but excluded 57 of these (Appendix 2) as they were rarely prescribed within primary care (n = 28, 42%), already used in cancer treatment (n = 21, 31%), typically given in topical or nasal spray formulations that are unlikely to have a systemic effect (n = 5, 7%), widely available over-the-counter (n = 2, 3%), or already known to influence breast cancer risk (n = 1, 1%). Of the 10 remaining substances, 6 were identified as potentially increasing (meloxicam, azithromycin, rizatriptan, citalopram, rosiglitazone, and verapamil) and 4 as potentially reducing (bendroflumethiazide, sertraline, fluvastatin, and budesonide) the risk of breast cancer.
| Pharmacoepidemiology data
We conducted a nested case-control study using the Clinical Practice
Research Datalink (CPRD). The CPRD contains computerized medical records from 674 general practices (approximately 7% of the UK population). 18 The practices are audited by the CPRD, and those meeting a predefined standard on data completeness and quality are deemed "up to research standard," and included in future extracts. Data recorded include patient demographics, clinical diagnoses (using Read codes), and prescription medication use. Previous research has found CPRD prescription and clinical information to be of high quality. [18] [19] [20] CPRD data were linked to the National Cancer Data Repository (NCDR) 21 to identify patients with a registry-confirmed breast cancer diagnosis, and to census information to derive Index of Multiple Deprivation scores. The NCDR holds UK-wide data on cancer registration from a variety of sources including general practitioners (GPs), cancer screening programs, NHS and private hospitals, and death certificates. 21 
| Cases and controls
In our primary analysis, cases were defined as patients with a first ever breast cancer diagnosis (ICD 10 code C50.0 to C50.9), identified from the NCDR cancer registry or GP records, between January 1, 1995
and December 31, 2010. This reflected a slight change from our initial analysis plan, which restricted cases to those with an NCDR-confirmed breast cancer diagnosis. We decided to use a broader case definition as recent evidence suggests that over 96% of breast cancers recorded within the CPRD can be validated using other data sources. 22 We conducted a secondary analysis restricted to NCDR-confirmed cases. Each case was matched to 1 control, who was breast cancer free on the cancer diagnosis date of the case, based on age (±1 year if no exact match available), year of diagnosis, and GP practice. The index date for the cases was their breast cancer diagnosis date. The index date of the controls was set equal to their matched case. The start of the exposure period was the latest of the patient's registration date at the practice, or when the practice's records were deemed to be "up to research standard." Cases and controls were included in the study if they had at least 3 years of "up to research standard" medical records before their index date. This was to ensure that there was adequate time to ascertain exposure status and measure confounders. Where cases and controls had different lengths of follow-up, these were truncated to the shortest period within the matched set to avoid time-window bias. 
KEY POINTS
• Several commonly used medications have been previously found to alter cancer risk.
• We applied a novel combined connectivity mapping and pharmacoepidemiological approach to identify new medications of potential interest.
• Overall, our combined connectivity mapping and pharmacoepidemiological approach did not identify any additional medications that were substantially associated with breast cancer risk.
• Additional work exploring the causes of our null results is required to refine this methodology for future studies.
Prescriptions in the year prior to the index date were excluded to prevent reverse causation. 24 We defined patients as users if they had at least 1 prescription for the candidate medication during the exposure period. To enable the testing of dose-response relationships, we extracted data on the medication prescribed, number of packs/tablets and medication strength, and calculated defined daily doses (DDDs).
The DDD system is a validated measure of drug consumption maintained by the World Health Organization. 25 27 We also adjusted for the use of aspirin, statins, metformin, digoxin, oral contraceptives, and hormone replacement therapy, as associations with breast cancer risk have been identified previously (Appendix 4). 8, 28, 29 We ignored confounders in the year prior to diagnoses to reduce reverse causation and overadjustment bias. 30 
| Statistical analysis
We calculated descriptive statistics and compared the demographics and clinical characteristics of the cases and controls. We used conditional logistic regression to estimate odds ratios (ORs) with 95% confidence intervals (CIs) for the association between medication use and breast cancer. We ranked medications by their connectivity score and plotted this against their OR to summarize our results. We used the Spearman rank correlation coefficient to formally test for an association between the connectivity score and effect estimate. The matched design of the study appropriately accounted for the effect of age, general practice, and year of diagnosis. We made additional adjustments for the presence of each comorbidity (yes/no), DCIS (yes/no), lifestyle factors (categorical), deprivation (quintiles), and other medication use (yes/no) using regression.
Although our main analysis was complete case, we also performed an additional sensitivity analysis using multiple imputation with chained equations (MICE) for smoking, alcohol consumption, and BMI. The imputation used ordered logit models with age and deprivation, separately for cases and controls. Briefly, MICE is a simulationbased approach for handling missing data, which leads to valid statistical inferences. 31 Sensitivity analyses were also conducted investigating the impact of excluding prescriptions in the 2 years prior to the index date (as opposed to one in the main analysis) and defining medication users as patients with at least 3 prescriptions (as opposed to 1 in the main analysis). Finally, we used Wald interaction tests to compare associations by age (dichotomized at 50 as this corresponds to the median menopausal age within the UK 32, 33 ) and estrogen receptor status (based on receipt of tamoxifen or aromatase inhibitors in the 6 months after breast cancer diagnosis), as risk factors have been shown to differ between these groups previously. 34, 35 3 | RESULTS
| Patient characteristics
We identified 45,147 cases of breast cancer in our primary analysis with a median exposure period of 7.8 years (min: 3.0, max: 27.1). Overall, cases and controls were very similar in their demographics, lifestyle, and clinical history, although a slightly larger proportion of cases had previously been prescribed hormone replacement therapy (28.5% vs 26.2%) and oral contraceptives (7.5% vs 6.6%) ( Table 1) .
| Association between medication use and breast cancer
Overall, there was little convincing evidence that any of the medications included in our study substantially altered breast cancer risk ( Table 2 ).
The adjusted ORs for ever use of azithromycin, rizatriptan, citalopram, rosiglitazone, sertraline, fluvastatin, and budesonide were between 0.95 and 1.05. There was some evidence that verapamil (OR: 1.16; 95% CI: 0.99, 1.37) and bendroflumethiazide use (OR: 1.11; 95% CI:
1.06, 1.15) was associated with increased breast cancer risk, although effect estimates were small. The ORs for each of the confounders included within our model are provided in Appendix 5.
There was no clear relationship between the connectivity score and the adjusted ORs for breast cancer risk (Spearman's correlation coefficient = −0.067; P value = .855). The 5 medications with the largest connectivity scores (meloxicam, azithromycin, rizatriptan, citalopram, and rosiglitazone) and the three with the lowest connectivity scores (budesonide, fluvastatin, and sertraline) had a small association with breast cancer, even among patients who received more than 1 year of treatment (Table 2 and Figure 1 ). Furthermore, bendroflumethiazide was identified as a potentially cancer-reducing medication in the connectivity mapping, yet we found an 11% (OR:
1.11; 95% CI: 1.06, 1.15) increase in breast cancer risk among users.
Our findings were similar when restricting cases to those with a NCDR-confirmed breast cancer diagnosis although, due to the smaller sample size, the CIs were noticeably wider in this analysis (Table 2 and Appendix 6).
| Sensitivity and subgroup analysis
In general, our conclusions were little altered in sensitivity analyses (Table 3) . Similar associations were observed when prescriptions were excluded in the 2 years prior to diagnosis (rather than 1) and when the definition of medication "ever use" was based upon 3 or more prescriptions (rather than 1). Using MICE to adjust for lifestyle factors (smoking, alcohol consumption, and obesity) resulted in similar estimates to the main, complete-case analysis. There was little evidence that any of the associations observed in our study differed according to menopausal or estrogen-receptor status (Appendix 7).
Discussion

| Main findings
In this instance, our combined connectivity mapping and pharmacoepidemiological approach did not identify any additional medications that were substantially associated with breast cancer risk.
Of the 6 medications expected to increase breast cancer risk, only verapamil had a noticeably higher risk, and this was relatively moderate in size (16%). None of 4 medications predicted to reduce breast cancer had meaningfully lower risk. Indeed for 1 of these, bendroflumethiazide, users had an 11% increased breast cancer risk compared with nonusers.
| Strengths and limitations
Our study is the first to combine connectivity mapping and pharmacoepidemiology to identify medications that may alter breast cancer. The utility and robustness of our connectivity mapping process have been tested in other drug discovery and repurposing research, 36, 37 while the large collection of gene expression profiles for FDA-approved medications facilitated a thorough analysis of potential connections with breast cancer risk. Our pharmacoepidemiology study is based on high-quality and nationally representative CPRD data with long follow-up (>7.5 years) for most patients. [18] [19] [20] We used prescribing data collected as part of routine clinical care, in many cases, several years before the onset of breast cancer that accurately reflects GP prescribing practices and negates the risk of recall bias.
Our study had several potential weaknesses. It is possible that the cell line models used during the connectivity mapping process do not accurately translate to human body. Furthermore, our connectivity mapping considered breast cancer as a single disease, potentially diluting important signals for specific breast cancer subtypes (e.g., triple negative cations, ductal carcinoma in situ, hemiplegia, mild liver disease, moderate liver disease, myocardial infarction, peptic ulcer disease, peripheral vascular disease, renal disease, and rheumatological disease), confounder medications (aspirin, digoxin, hormone replacement therapy, metformin, oral contraceptive, and statin), deprivation, smoking status, alcohol consumption, and obesity. Additionally conditioned on age, GP practice, and year of diagnosis.
We do not know if patients adhered to their prescribed medications; however, our main conclusions were similar when restricting our analysis to patients who received multiple prescriptions (>365 DDDs), where noncompliance is less of a concern. Additionally, GP records do not contain data on over-the-counter medications, which may have impaired our ability to accurately adjust for aspirin use (due to misclassification). Pharmacoepidemiology can only be used for commonly prescribed medications; other methodological approaches, such as cell or animal models, may be more suitable for rarer medications. Our study included a large number of medications that increased the probability of false-positive findings; therefore, any "statistically significant" results, specifically for bendroflumethiazide, should be interpreted with appropriate caution. Lastly, some of the medications explored in our analysis were rarely used within the UK general practice population. This may have led to lower power to detect differences in breast cancer risk between users and nonusers, particularly in our subgroup analyses.
| Comparisons with other research
To our knowledge, this is the first study to combine connectivity mapping and pharmacoepidemiology to identify medications that alter breast cancer risk. Of the medications we considered, only rosiglitazone has been previously investigated in studies of breast cancer risk, with a recent meta-analysis reporting no evidence of an association, which was in keeping with our results. 40 None of the other medications included in our study have been investigated specifically;
however, studies of their drug class were common and are potentially informative. In general, these were consistent with our study findings;
for example, meta-analyses of nonsteroidal antiinflammatory drugs (meloxicam), 41 antibiotics (azithromycin), 42 selective serotonin reuptake inhibitors (citalopram and sertraline), 43 and statins (fluvastatin) 44 have all reported weak associations. Our finding of increased breast cancer risk among verapamil users is consistent with a recent metaanalysis of long-term calcium channel blocker users, 45 while our estimate of 11% increased breast cancer risk among bendroflumethiazide users is similar to the results of 2 US-based studies of thiazide diuretics, 46,47 although a third found no association. 48 We found no studies investigating the association between rizatriptan or budesonide use (or their drug classes) and breast cancer risk.
| Implications
Breast cancer places an important burden on population health, accounting for 520,000 deaths in Europe annually and €15 billion in costs. 2, 7 An improved understanding of the etiology of breast cancer, or finding new cost-effective treatment options, could lead to better patient outcomes and financial savings. Although our combined connectivity mapping and pharmacoepidemiology approach theoretically offers an attractive way to achieve these goals, we did not to identify any new medications that were substantially associated with breast cancer risk.
There are several potential reasons why the findings from the connectivity mapping process did not translate into observable differences in breast cancer risk among medication users. First, this could reflect the weaknesses of connectivity mapping, perhaps due to a reliance on cell cultures, and difficulty interpreting connectivity scores. 13 It may be that the doses prescribed in routine clinical practice are insufficiently large for the cancer causing or protective effects identified during the connectivity mapping to become apparent. Further laboratory-based in vitro models could be used to prescreen an initial list of medications derived from connectivity mapping and exclude those where the required dose is unlikely to be achieved. Our study combined gene expression information from 68 distinct datasets. Although we aimed to remove potential "batch effects," it could be that intersample heterogeneity has obfuscated true differences between normal and breast cancer cells. Second, it is possible that the true effects of medication use are masked by the limitations of an observational study design. For example, nondifferential misclassification of drug exposure (due to medication nonadherence) would be expected to attenuate our estimates toward the null effect, while residual confounding could bias our estimates in either direction. 49 However, given the consistently small associations found across the diverse range of medications included in our study, it seems unlikely that these factors are solely driving our results. Additional work exploring the causes of our null results is required to refine this methodology for future studies.
Our finding of moderately increased breast cancer risk among verapamil and bendroflumethiazide users could require further investigation. These associations are broadly consistent with the findings from previous studies of their drug classes, [45] [46] [47] and plausible biological mechanisms exist for their use to increase breast cancer risk.
Specifically, calcium channel blockers are known to interfere with apoptosis, which could facilitate the division of cells with a malignant potential, 50, 51 and thiazide diuretics may increase insulin resistance, an accepted risk factor for breast cancer.
52,53
| CONCLUSIONS
In this instance, our combined connectivity mapping and pharmacoepidemiological approach did not identify any additional medications which were substantially associated with breast cancer risk. The cause of this is unknown; however, it could be due to limitations in the connectivity mapping, such as implausible dosage requirements, or the pharmacoepidemiology, such as residual confounding. Additional work exploring the causes of our null results is required to refine this methodology for future studies. There was some evidence that verapamil and bendroflumethiazide users had slightly higher breast cancer risk; however, further confirmatory studies are required.
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